[해외주식] $ADXS 포물선! / $ADXS Parabolic!
주식개미
0
2199
2021.07.02 15:31
Advaxis, Inc
Rocky88888888888
$ADXS Parabolic! entry PTs .26-.44-.47 Target PTs 1.25-1.40-10-22-400 possible Risky, Clinical stage Bio
RS Ratio: 1/15 on 3/29/2019
Wyckoff Re-accumulation after decline, MMs loading at Support level
Strong Influx of Volume
Advaxis , Inc. , a clinical-stage biotechnology company, focuses on the discovery , development, and commercialization of proprietary Listeria monocytogenes ( Lm ) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc. ; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited ; Global BioPharma Inc. ; Knight Therapeutics Inc ; and others. Advaxis , Inc. was founded in 2002 and is based in Princeton, New Jersey.
RS Ratio: 1/15 on 3/29/2019
Wyckoff Re-accumulation after decline, MMs loading at Support level
Strong Influx of Volume
Advaxis , Inc. , a clinical-stage biotechnology company, focuses on the discovery , development, and commercialization of proprietary Listeria monocytogenes ( Lm ) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc. ; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited ; Global BioPharma Inc. ; Knight Therapeutics Inc ; and others. Advaxis , Inc. was founded in 2002 and is based in Princeton, New Jersey.
번역:
애드팩시, 주식회사
로키88888888
$ADXS 포물선! 입력 PT.26-.44-.47 대상 PT 1.25-1.40-10-22-400 가능한 위험, 임상 단계 바이오
RS 비율: 2019년 3월 29일 1/15
감소 후 Wyckoff 재축적, 지원 레벨에서 MM 로드
강력한 볼륨 유입
임상 단계 생명공학 회사인 Advaxis, Inc.는 미국에서 독점적인 Listeria monocytogenes(Lm) 기술 항원 전달 제품의 발견, 개발 및 상업화에 초점을 맞추고 있다. 전이성 전립선암 치료를 위한 임상 2상인 ADXS-PSA, 비소세포 폐암 치료를 위한 임상 1/2상인 ADXS-503, 전립선암 치료를 위한 ADXS-504 등을 개발하고 있다. 또한 LmTechnology 면역 요법에 대한 임상 연구도 진행 중에 있으며, 다음의 질병 중심 핫스팟/오프-스토어 신 항원 유도 요법, 인유두종 바이러스 관련 암, 전립선암에 대한 임상 연구를 수행하고 있다. 이 회사는 Merck & Co., Inc.; OS 치료사, LLC; Aratana Therapeics Inc.와 협력 및 파트너십을 맺고 있습니다. Biocon Limited; Global BioParma Inc., Knight Therapeics Inc. 및 기타 회사. Advaxis, Inc.는 2002년에 설립되었으며 뉴저지주 프린스턴에 본사를 두고 있다.
원문링크: https://www.tradingview.com/chart/ADXS/9S4J1Dcp-ADXS-Parabolic/
[본문뒤 추가문구] 서학개미 투자포럼 - 해외투자 트렌드의 중심
